However, the clinical trial TRANSLATE-TIMI 70 was discontinued in early 2022 because of serious hepatic steatosis, and an increase in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were observed as adverse effects [64]. The gene discussed is GPT; the disease is fatty liver disease.